DEIDRA KNAUTH: Open Payments
NPI 1679139075 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$705 in 33 payments from 15 companies in 2025. Trend: 2023 $3,230 · 2024 $1,666 · 2025 $705
Food & beverage: $705
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $108 |
| Novo Nordisk Inc | 3 | $72 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Amgen Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $59 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
Products named: VRAYLAR, VOQUEZNA, TRELEGY ELLIPTA, XIFAXAN, JARDIANCE, MOUNJARO, GEMTESA, Ozempic.
Industry payments across NY — which companies pay providers there.
